Skip to Main text
Nitto always aims for fair disclosure to ensure that our investors can properly evaluate our corporate value.
|2016/Nov/11||Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with Nitto Denko for Targeted siRNA Therapy in Advanced Non-alcoholic Steatohepatitis (NASH) and Cirrhosis Due to NASH|
|2016/Nov/02||Initiation of Phase I Clinical Trial for Seasonal Influenza HA Vaccine Sublingual Tablet|
|2016/Oct/31||Notice Regarding Dividends from Surplus and Revision of Dividend Forecast|
Back to Page Top